دورية أكاديمية
Changing concepts in multiple myeloma: from conventional chemotherapy to high-dose treatment.
| العنوان: | Changing concepts in multiple myeloma: from conventional chemotherapy to high-dose treatment. |
|---|---|
| المؤلفون: | Sonneveld P; Erasmus M C, Department of Hematology, Room L407, PO Box 2040, 3000 CA Rotterdam, The Netherlands. sonneveld@hema.fgg.eur.nl, Segeren CM |
| المصدر: | European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2003 Jan; Vol. 39 (1), pp. 9-18. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print Cited Medium: Print ISSN: 0959-8049 (Print) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Oxford : Elsevier Science Ltd Original Publication: Oxford ; New York : Pergamon Press, c1990- |
| مواضيع طبية MeSH: | Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Hematopoietic Stem Cell Transplantation/*methods , Multiple Myeloma/*therapy, Antineoplastic Agents, Alkylating/administration & dosage ; Clinical Trials, Phase II as Topic ; Humans ; Melphalan/administration & dosage ; Randomized Controlled Trials as Topic ; Recurrence |
| مستخلص: | The treatment of Multiple Myeloma (MM), a malignant plasma cell disorder has changed considerably over the past decade. It has been convincingly shown that intensive treatment supported by autologous stem cell reinfusion is superior to conventional chemotherapy with alkylating agents or vincristine, doxorubicin and dexamethasone (VAD) alone in terms of a more rapid response and a longer disease-free survival. However, cure is not achieved in the majority of patients. Several trials have therefore focussed on repeated intensive treatments in order to improve the survival of these patients. Other approaches are aimed at identifying patients on the basis of prognostic factors, who may benefit from high-dose therapy. This review discusses the recent developments in intensive therapy for multiple myeloma. |
| Number of References: | 88 |
| المشرفين على المادة: | 0 (Antineoplastic Agents, Alkylating) Q41OR9510P (Melphalan) |
| تواريخ الأحداث: | Date Created: 20021231 Date Completed: 20030404 Latest Revision: 20190718 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1016/s0959-8049(02)00503-8 |
| PMID: | 12504653 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 0959-8049 |
|---|---|
| DOI: | 10.1016/s0959-8049(02)00503-8 |